FY2025 · ended Dec 31, 2025 · Revenue $12,353, +256.0% YoY · Filed Mar 31, 2026
Yubo International Biotech Limited (YBGJ) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $12,353 and a net loss of $1.1 million. As of Jun 30, 2026 it held $11,989 in cash and investments and $15,655 in total debt.
Revenue (TTM)
$12,353
+68727.8% vs year-ago TTM
Net income (TTM)
$-1.06M
+25.0% vs year-ago TTM
Operating cash flow (TTM)
$-727,992
+26.1% vs year-ago TTM
Free cash flow
$-600,953
+62.1% vs prior year
EPS (TTM)
$-0.01
Dividend per share
None
Shares outstanding
170.42M
+42.2% vs prior year
Net cash
$-3,666
as of Jun 30, 2026
Operating margin
-9096.9%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- YBGJ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Beijing, China
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 895464
- Former names
- MAGNA LAB INC (until Dec 4, 2020)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $12,353 | $3,470 | $604,676 | $104,283 | — |
| Operating income | -$1.2M | -$1.8M | -$1.2M | -$1.2M | -$1.5M |
| Net income | -$1.1M | -$1.8M | -$1.2M | -$1.2M | -$1.5M |
| Diluted EPS | -$0.01 | -$0.02 | — | — | — |
| Operating cash flow | -$842,802 | -$1.3M | -$738,971 | -$600,953 | -$1.0M |
| Free cash flow | — | — | — | -$600,953 | -$1.6M |
| Total assets | $847,094 | $1.5M | $1.7M | $2.3M | $4.6M |
| Total liabilities | $2.8M | $4.8M | $3.5M | $2.9M | $4.7M |
| Stockholders' equity | -$2.0M | -$3.4M | -$1.8M | -$565,373 | -$131,198 |
| Cash and investments | $8,062 | $7,015 | $6,359 | $18,220 | $27,517 |
| Total debt | $78,782 | $478,765 | $391,913 | $790,499 | $293,985 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jun 12, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Auditor change
|
Jan 16, 2026 | Jan 13, 2026 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 284 Yubo International Biotech Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.